美国拥有世界上最大的医疗市场。如今,该市场相当热闹。据调查公司Cegedim Strategic Data 称,2017年制药企业为了向医生推销药品,所花费用超过240亿美元;根据德勤去年做的一份调查显示,35%的医生接受了制药行业的宴请或其提供的免费旅游,而16%的医生收受了咨询费,或者说演讲费。大部分州的医生为维持医师资格证,需要定期接受培训。2011年美国继续医学教育认证委员会(Accreditation Council for Continuing Medical Education)发现,其追踪调查的医学培训机构中有近1/3是由医药和器械公司赞助。
Such chumminess has long raised fears about undue influence. In 2008 two health-industry groups set tighter, voluntary standards for companies. In 2009 America’s Institute of Medicine, an advisory body, urged much stricter regulation to prevent conflicts of interest.
一直以来,人们都担心医商之间的这种亲密无间会带来不好的影响。2008年,两家医疗健康产业集团为企业制定了更严格的自愿性质标准。2009年,美国顾问团医院研究所(America’s Institute of Medicine)敦促要加强监管力度,防止利益纠纷。
Legislative action, though, has been slow, especially at the federal level. The Sunshine law, passed as part of Barack Obama’s health reform, is the first national requirement for transparency. Each year drug and device firms must disclose payments and other “transfers of value” to doctors. They must also report research fees and doctors’ investment interests. The first filing will appear on a public database by September 30th, 2017.
【揭露药医利益关系的新招】相关文章:
最新
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15